by Penazzato M, Hafiz A, Morin S, Malik F, Cappello B, Cohn J, Cressey TR, Fassinou P, Garcia-Prats AJ, Hatane L, Lee J, Masini T, Ojoo A, Ruel T, Villafranca DR, Valentin M, Reeder JC. The Lancet Child & Adolescent Health 2025, 9859: 337-348. doi: 10.1016/S2352-4642(25)00040-9
Summary: The Global Accelerator for Paediatric Formulations (GAP-f), a WHO-hosted network established in 2020, has united 33 partners to promote innovation and access to child-friendly formulations. The authors of this Personal View describe learnings from Phase 2 (2022–24) of GAP-f's work, including the need to adapt prioritisation processes to diverse therapeutic areas and focus on high-impact areas based on unmet needs. Platform trials emerged as a promising tool to accelerate evidence generation, but operational challenges and funding constraints must be overcome. Development of paediatric formulations must be incentivised for these small volume markets, and, once developed, political will and community engagement are essential to creating demand, supporting roll out, and ensuring equitable access to these products.
